Chart: Sponsors Go 2 For 4 At ODAC With Pazdur On The Mound
An extended baseball analogy by some committee members is as close as sponsors came to hitting anything out of the park during the Sept. 1-2 meeting of FDA's Oncologic Drugs Advisory Committee. ODAC agreed with FDA that randomized controlled trials - which none of the four drugs reviewed had - were needed for approval, but members were less adamant about that principle when applying it might mean leaving patients on base.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth